Ucb 34714    (DrugBank: -)

2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
149片側痙攣・片麻痺・てんかん症候群1
309進行性ミオクローヌスてんかん6

149. 片側痙攣・片麻痺・てんかん症候群 [臨床試験数:22,薬物数:33(DrugBank:12),標的遺伝子数:13,標的パスウェイ数:17
Searched query = "Hemiconvulsion hemiplegia epilepsy syndrome", "One side convulsions", "Hemiplegia", "Epilepsy syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 22 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-JapicCTI-173615
22/8/201715/06/2017A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam Subjects (>=16 to 80 Years of Age) With Partial Seizures With or Without Secondary GeneralizationA Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam Subjects (>=16 to 80 Years of Age) With Partial Seizures With or Without Secondary Generalization Epilepsy and epilepsy syndromeIntervention name : ucb 34714
INN of the intervention : Brivaracetam
Dosage And administration of the intervention : Oral administration
Control intervention name : Placebo
INN of the control intervention : -
Dosage And administration of the control intervention : -
UCB Japan Co., Ltd.NULLrecruiting1680BOTH444Phase 3Japan, Asia except Japan

309. 進行性ミオクローヌスてんかん [臨床試験数:11,薬物数:15(DrugBank:2),標的遺伝子数:4,標的パスウェイ数:9
Searched query = "Progressive myoclonus epilepsy", "Unverricht-Lundborg disease", "Lafora disease", "Benign adult familial myoclonus epilepsy", "BAFME"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
6 / 11 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2006-000169-12-NL
(EUCTR)
27/12/200628/09/2006A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease.A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. Patients with genetically ascertained Unverricht-Lundborg disease (ULD).
MedDRA version: 8.1;Level: LLT;Classification code 10054894;Term: Unverricht-Lundborg disease
Product Name: Brivaracetam
Product Code: ucb 34714
INN or Proposed INN: brivaracetam
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide
Product Name: Brivaracetam
Product Code: ucb 34714
INN or Proposed INN: brivaracetam
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide
UCB S.A.NULLNot RecruitingFemale: yes
Male: yes
42Finland;Netherlands;France;Italy;Sweden
2EUCTR2006-001536-46-FI
(EUCTR)
21/11/200610/10/2006A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. - ULD trialA multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. - ULD trial Patients with genetically ascertained Unverricht-Lundborg disease (ULD).
MedDRA version: 8.1;Level: LLT;Classification code 10054894;Term: Unverricht-Lundborg disease
Product Name: Brivaracetam
Product Code: ucb 34714
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-y1] butanamide
Product Name: Brivaracetam
Product Code: ucb 34714
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-y1] butanamide
Product Name: Brivaracetam
Product Code: ucb 34714
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-y1] butanamide
UCB S.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
42Finland;France
3EUCTR2006-001536-46-FR
(EUCTR)
14/11/200625/08/2006A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. - ULD trialA multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. - ULD trial Patients with genetically ascertained Unverricht-Lundborg disease (ULD).
MedDRA version: 8.1;Level: LLT;Classification code 10054894;Term: Unverricht-Lundborg disease
Product Name: Brivaracetam
Product Code: ucb 34714
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-y1] butanamide
Product Name: Brivaracetam
Product Code: ucb 34714
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-y1] butanamide
Product Name: Brivaracetam
Product Code: ucb 34714
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-y1] butanamide
UCB S.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
42Finland;France
4EUCTR2006-000169-12-FR
(EUCTR)
03/11/200625/08/2006A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease.A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. Patients with genetically ascertained Unverricht-Lundborg disease (ULD).
MedDRA version: 8.1;Level: LLT;Classification code 10054894;Term: Unverricht-Lundborg disease
Product Name: Brivaracetam
Product Code: ucb 34714
INN or Proposed INN: brivaracetam
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide
Product Name: Brivaracetam
Product Code: ucb 34714
INN or Proposed INN: brivaracetam
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide
UCB S.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
42Finland;Netherlands;France;Italy;Sweden
5EUCTR2006-000169-12-SE
(EUCTR)
06/10/200607/08/2006A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease.A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. Patients with genetically ascertained Unverricht-Lundborg disease (ULD).
MedDRA version: 8.1;Level: LLT;Classification code 10054894;Term: Unverricht-Lundborg disease
Product Name: Brivaracetam
Product Code: ucb 34714
INN or Proposed INN: brivaracetam
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide
Product Name: Brivaracetam
Product Code: ucb 34714
INN or Proposed INN: brivaracetam
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide
UCB Pharma S.A.NULLNot RecruitingFemale: yes
Male: yes
45Finland;Netherlands;France;Italy;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2006-000169-12-FI
(EUCTR)
28/09/200631/07/2006A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease.A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. Patients with genetically ascertained Unverricht-Lundborg disease (ULD).
MedDRA version: 8.1;Level: LLT;Classification code 10054894;Term: Unverricht-Lundborg disease
Product Name: Brivaracetam
Product Code: ucb 34714
INN or Proposed INN: brivaracetam
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide
Product Name: Brivaracetam
Product Code: ucb 34714
INN or Proposed INN: brivaracetam
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide
UCB S.A.NULLNot RecruitingFemale: yes
Male: yes
42Finland;Netherlands;France;Italy;Sweden